Letrozole in Stimulated IVF Cycles
Launched by THE UNIVERSITY OF HONG KONG · Sep 20, 2016
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
Trial design:
Infertile women undergoing IVF treatment will be randomized into one of the following two groups by an online randomization program:
Letrozole group: letrozole 2.5mg daily will be given at the start of the antagonist during ovarian stimulation i.e. day 5 of stimulation.
Control group: standard care with FSH alone during ovarian stimulation.
Intervention:
Subjects can be put on oral contraceptive pill in the preceding cycle for scheduling stimulation. On day 2-3, a pelvic ultrasound will be performed for antral follicle count.
Letrozole group:
Daily 150-225 IU human meno...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • women under 42 years of age
- • medical indication for IVF treatment
- • antral follicle count prior to ovarian stimulation \>=3
- • informed consent
- Exclusion Criteria:
- • women using donor oocytes
- • women undergoing preimplantation genetic diagnosis
- • women with abnormal uterine cavity shown on hysterosalpingogram or saline infusion sonogram
- • women with hydrosalpinges shown on scanning and not corrected
- • previous documented poor response (\<=3 oocytes) to ovarian stimulation using at least FSH 225 IU daily
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Hong Kong, Hong Kong, China
Patients applied
Trial Officials
Ernest HY Ng, MD
Principal Investigator
Department of Obstetrics and Gynaecology, The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials